Drug curbs albuminuria, cholesterol in type 2 diabetes, nephropathy

06/5/2013 | Medscape (free registration)

A study presented at the European Renal Association-European Dialysis and Transplant Association meeting found patients with type 2 diabetes and nephropathy who received atrasentan attained improvements in albuminuria and bad cholesterol and triglyceride levels at 12 weeks compared with those who took a placebo. However, the findings merit further and longer-term assessment to see whether the drug would be beneficial, a researcher said.

View Full Article in:

Medscape (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY